|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION |
|||||
|
|
|||||
|
________________________________________ FORM 8-K |
|||||
|
CURRENT REPORT PURSUANT |
|||||
|
|
|||||
|
Date of report (Date of earliest event reported): October 30, 2006 |
|||||
|
GENTA INCORPORATED |
|||||
|
(Exact Name of Registrant as Specified in Its Charter) |
|||||
|
Delaware |
|||||
|
(State or Other Jurisdiction of Incorporation) |
|||||
|
0-19635 |
33-0326866 |
||||
|
(Commission File Number) |
(IRS Employer Identification No.) |
||||
|
200 Connell Drive |
07922 |
||||
|
(Address of Principal Executive Offices) |
(Zip Code) |
||||
|
(908) 286-9800 |
|||||
|
(Registrant’s Telephone Number, Including Area Code) |
|||||
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
Pre -commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
Pre -commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On October 30, 2006, Genta Incorporated (NASDAQ: GNTA) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has notified the Company that it has extended the review period for the currently pending New Drug Application (NDA) for Genasense® (oblimersen sodium) Injection plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
The press release is attached hereto as Exhibit 99.1and is incorporated herein by reference. The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
Description |
|
|
99.1 |
Press Release of the Company dated October 30, 2006 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
GENTA INCORPORATED |
|||
|
Date: |
October 30, 2006 |
|
By: |
/s/ RICHARD J. MORAN |
|
|
|
|
|
|
Name: |
Richard J. Moran |
|
|
|
|
|
Title: |
Senior Vice President, Chief Financial Officer and Corporate Secretary |
EXHIBIT INDEX
|
Exhibit |
Description |
Sequentially |
|
99.1 |
Press Release of the Company dated October 30, 2006
|
|